Curr Opin Immunol. 2025 Jul 10;96:102606. doi: 10.1016/j.coi.2025.102606. Online ahead of print.
ABSTRACT
Biological therapy has revolutionized the treatment landscape of complex and chronic conditions, including autoimmune diseases and cancer. However, their high costs have significantly limited patient access, particularly in low- and middle-income regions, such as Latin America and the Caribbean (LAC). As cost-effective alternatives, biosimilars have shown the potential to transform this paradigm and improve access to care. This narrative review examines the role of biosimilars in transforming health care across LAC. It highlights their potential to reduce treatment costs, expand access to essential medicines, promote market competition, and ease financial pressures on health systems. The biosimilars industry in LAC is expected to experience accelerated growth, driven by regulatory enhancements, market dynamics, investments, and a greater emphasis on education. Developing the biosimilar industry will improve health care resiliency, economic stability, and patient access throughout LAC.
PMID:40644746 | DOI:10.1016/j.coi.2025.102606